Literature DB >> 19026269

Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features.

Anne Berghöfer1, Martin Alda, Mazda Adli, Christopher Baethge, Michael Bauer, Tom Bschor, Tasha Glenn, Paul Grof, Bruno Müller-Oerlinghausen, Janusz Rybakowski, Alexandra Suwalska, Andrea Pfennig.   

Abstract

OBJECTIVE: Poor response to long-term lithium treatment has been reported to be associated with atypical features of bipolar disorder. The purpose of this study was to investigate the influence of atypical symptoms on the effectiveness and stability of long-term lithium treatment in a prospective, multicenter cohort of bipolar patients in a naturalistic setting.
METHOD: Patients were initially selected according to International Classification of Diseases, 8th Revision, criteria for bipolar disorder and required long-term treatment. Their diagnoses were reconfirmed according to DSM-IV upon its publication. They were prospectively followed for an approximately 20-year period ending in 2004 in 5 centers participating in the International Group for the Study of Lithium-Treated Patients. Examinations included a comprehensive psychiatric evaluation, an assessment of typical and atypical features on an 8-item scale, and an evaluation of clinical course using the morbidity index. Unbalanced repeated-measures regression models with structured covariance matrices were used to assess the extent to which the morbidity index was influenced by atypical symptoms, duration of treatment, and pretreatment features.
RESULTS: A total of 242 patients were followed for a mean period of 10 years. In 142 patients, the number of typical features was greater than the number of atypical features, whereas in 100 patients the number of atypical features was greater than or equal to the number of typical features. The mean morbidity index remained stable over a period of 20 years in both groups of patients and was not significantly associated with the presence of atypical features, the duration of lithium treatment, the number or frequency of episodes, or latency from the onset of bipolar disorder to the start of lithium treatment.
CONCLUSION: Our study suggests that long-term response to lithium maintenance treatment is stable both in patients with typical and in patients with atypical features. The predominance of either typical or atypical features did not result in different responses to long-term lithium treatment in this sample of bipolar patients. Copyright 2008 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026269     DOI: 10.4088/jcp.v69n1203

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

Review 1.  Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence.

Authors:  Anne Duffy
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

2.  Staging model raises fundamental questions about the nature of bipolar disorder.

Authors:  Martin Alda; Flavio Kapczinski
Journal:  J Psychiatry Neurosci       Date:  2016-08       Impact factor: 6.186

3.  Who are excellent lithium responders and why do they matter?

Authors:  Martin Alda
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses.

Authors:  Catalina Lopez de Lara; Iris Jaitovich-Groisman; Cristiana Cruceanu; Firoza Mamdani; Véronique Lebel; Volodymyr Yerko; Angus Beck; L Trevor Young; Guy Rouleau; Paul Grof; Martin Alda; Gustavo Turecki
Journal:  Int J Neuropsychopharmacol       Date:  2010-07-29       Impact factor: 5.176

6.  Predictors of lithium response in bipolar disorder.

Authors:  Sarah K Tighe; Pamela B Mahon; James B Potash
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

7.  Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients.

Authors:  Anne Berghöfer; Martin Alda; Mazda Adli; Christopher Baethge; Michael Bauer; Tom Bschor; Paul Grof; Bruno Müller-Oerlinghausen; Janusz K Rybakowski; Alexandra Suwalska; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2013-07-31

8.  GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder.

Authors:  Chih-Ken Chen; Chau-Shoun Lee; Hsuan-Yu Chen; Lawrence Shih-Hsin Wu; Jung-Chen Chang; Chia-Yih Liu; Andrew Tai-Ann Cheng
Journal:  BJPsych Open       Date:  2016-09-08

9.  Towards the clinical implementation of pharmacogenetics in bipolar disorder.

Authors:  Naji C Salloum; Michael J McCarthy; Susan G Leckband; John R Kelsoe
Journal:  BMC Med       Date:  2014-05-30       Impact factor: 8.775

10.  Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder.

Authors:  J Song; S E Bergen; A Di Florio; R Karlsson; A Charney; D M Ruderfer; E A Stahl; K D Chambert; J L Moran; K Gordon-Smith; L Forty; E K Green; I Jones; L Jones; E M Scolnick; P Sklar; J W Smoller; P Lichtenstein; C Hultman; N Craddock; M Landén; Jordan W Smoller; Roy H Perlis; Phil Hyoun Lee; Victor M Castro; Alison G Hoffnagle; Pamela Sklar; Eli A Stahl; Shaun M Purcell; Douglas M Ruderfer; Alexander W Charney; Panos Roussos; Carlos Pato Michele Pato; Helen Medeiros; Janet Sobel; Nick Craddock; Ian Jones; Liz Forty; Arianna Di Florio; Elaine Green; Lisa Jones; Katherine Gordon-Smith; Mikael Landen; Christina Hultman; Anders Jureus; Sarah Bergen; Steven McCarroll; Jennifer Moran; Jordan W Smoller; Kimberly Chambert; Richard A Belliveau
Journal:  Mol Psychiatry       Date:  2015-10-27       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.